CA2460587A1 - Anti-pdgf antibodies and methods for producing engineered antibodies - Google Patents

Anti-pdgf antibodies and methods for producing engineered antibodies Download PDF

Info

Publication number
CA2460587A1
CA2460587A1 CA002460587A CA2460587A CA2460587A1 CA 2460587 A1 CA2460587 A1 CA 2460587A1 CA 002460587 A CA002460587 A CA 002460587A CA 2460587 A CA2460587 A CA 2460587A CA 2460587 A1 CA2460587 A1 CA 2460587A1
Authority
CA
Canada
Prior art keywords
antibody
sequence
library
panel
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002460587A
Other languages
English (en)
French (fr)
Inventor
Katherine S. Bowdish
Shana Frederickson
Anke Kretz-Rommel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2460587A1 publication Critical patent/CA2460587A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002460587A 2001-09-20 2002-09-20 Anti-pdgf antibodies and methods for producing engineered antibodies Abandoned CA2460587A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US32353701P 2001-09-20 2001-09-20
US32354401P 2001-09-20 2001-09-20
US60/323,537 2001-09-20
US60/323,544 2001-09-20
US37999402P 2002-05-13 2002-05-13
US60/379,980 2002-05-13
PCT/US2002/030086 WO2003025019A1 (en) 2001-09-20 2002-09-20 Anti-pdgf antibodies and methods for producing engineered antibodies

Publications (1)

Publication Number Publication Date
CA2460587A1 true CA2460587A1 (en) 2003-03-27

Family

ID=27406282

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002460587A Abandoned CA2460587A1 (en) 2001-09-20 2002-09-20 Anti-pdgf antibodies and methods for producing engineered antibodies

Country Status (4)

Country Link
EP (1) EP1436329A4 (https=)
JP (1) JP2005512962A (https=)
CA (1) CA2460587A1 (https=)
WO (1) WO2003025019A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002359568B2 (en) 2001-12-03 2008-02-21 Alexion Pharmaceuticals, Inc. Hybrid antibodies
US7393648B2 (en) 2001-12-03 2008-07-01 Alexion Pharmaceuticals, Inc. Hybrid antibodies
US20040009178A1 (en) * 2002-02-11 2004-01-15 Bowdish Katherine S. Immunotherapeutics for biodefense
JP2007525458A (ja) * 2003-04-23 2007-09-06 メダレックス インコーポレイテッド インターフェロンα受容体−１（ＩＦＮＡＲ−１）に対するヒト化抗体
NZ592039A (en) * 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
EP1737890A2 (en) * 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
WO2009129538A2 (en) * 2008-04-18 2009-10-22 Xencor, Inc. Human equivalent monoclonal antibodies engineered from nonhuman variable regions
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099364A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
NZ629697A (en) 2012-03-15 2017-01-27 Janssen Biotech Inc Human anti-cd27 antibodies, methods and uses
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2014001442A1 (en) * 2012-06-28 2014-01-03 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
RU2676102C2 (ru) 2012-09-27 2018-12-26 Аллерган, Инк. Биодеградируемые системы доставки лекарственных средств для долговременного высвобождения белков
JP6649246B2 (ja) 2013-03-14 2020-02-19 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ タンパク質の徐放性送達の組成物及び製造プロセス中のタンパク質の安定化方法
DK4374873T3 (da) 2013-07-12 2025-11-03 Astellas Us Llc Middel til brug ved behandling eller forebyggelse af oftalmologiske tilstande
JP2019006732A (ja) * 2017-06-27 2019-01-17 学校法人東京理科大学 Ｍｙｃタンパク質阻害剤、Ｍｙｃタンパク質阻害方法、抗神経芽腫剤及びＭｙｃタンパク質の過剰発現を伴う疾患の治療方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5817310A (en) * 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
US5976534A (en) * 1993-02-25 1999-11-02 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
WO1999024059A1 (en) * 1997-11-07 1999-05-20 Massachusetts Institute Of Technology Pdgf-mediated microvascular communication and methods of use thereof
DK1034298T3 (da) * 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof

Also Published As

Publication number Publication date
EP1436329A4 (en) 2005-04-27
WO2003025019A1 (en) 2003-03-27
EP1436329A1 (en) 2004-07-14
JP2005512962A (ja) 2005-05-12
WO2003025019A9 (en) 2004-05-06
WO2003025019A8 (en) 2004-04-01

Similar Documents

Publication Publication Date Title
US20030219839A1 (en) Anti-PDGF antibodies and methods for producing engineered antibodies
CA2460587A1 (en) Anti-pdgf antibodies and methods for producing engineered antibodies
Schier et al. Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection
Chiu et al. Engineering antibody therapeutics
CN100480269C (zh) 抗-血管内皮生长因子的抗体
JP5685274B2 (ja) 結合タンパク質の混合物
CN101210050B (zh) 抗-血管内皮生长因子的抗体
US20190031770A1 (en) Intercalated single-chain variable fragments
CN112646032B (zh) 靶向bcma的具有人猴交叉的人源化单克隆抗体
JP2015524404A (ja) 高度に保存された標的に対するラクダ科動物由来の配列を含む抗体
JP2010260845A (ja) Ｍｎ結合および細胞接着中和活性を有するヒト抗体
JP7624478B2 (ja) 癌治療において壊死を標的とするヒト化抗核抗体
EP2986640B1 (en) Humanized antibody against interleukin-20 and treatment for inflammatory diseases
US20060024666A1 (en) Humanized antibodies against the venezuelan equine encephalitis virus
CN110642947B (zh) 抗人cd147的单克隆抗体、表达载体、细胞株及其应用
JP2026509245A (ja) 抗体およびその使用
AU2002341785A1 (en) Anti-PDGF antibodies and methods for producing engineered antibodies
Padoa et al. Engineered antibodies: A new tool for use in diabetes research
EP1747015B1 (en) Solution phase biopanning method using engineered decoy proteins
JT George et al. Section Review Biologicals & Immunologicals: Advances in antibody engineering
US20260028399A1 (en) Human-like target-binding proteins
Putelli Human antibody phage technology-isolation and characterization of monoclonal antibodies for the targeting of cancer and rheumatoid arthritis

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20080922